Guiyang's chemical pharma park powers ahead with full-chain development

Guiyang Health and Pharmaceutical (Chemical) Industrial Park in Xifeng county, Guizhou's only industrial park dedicated to chemical active pharmaceutical ingredients (APIs) and new medicines, is rapidly emerging as a key driver in the province's pharmaceutical landscape.

Guiyang Health and Pharmaceutical (Chemical) Industrial Park in Xifeng. [Photo/xifeng.gov.cn]

Targeting intermediates, APIs, and formulation production, the park has attracted seven pharmaceutical companies, including Guizhou Kaben Kangda Biotechnology Co and Sichuan Chenghua Biotechnology Co, establishing a full-chain ecosystem from R&D to manufacturing and services.

Covering 4,084 mu (272 hectares), the park is advancing with a total investment of 1.47 billion yuan ($203.73 million). Construction sites bustle with activity as modern production facilities take shape. Chenghua's 25,000-square-meter smart plant is nearly ready for trial production and will manufacture high-value compounds like tauroursodeoxycholic acid and obeticholic acid. Its first phase is expected to open in the second quarter this year, generating 150 million yuan in annual output and creating 50 new positions.

Kaben Kangda is preparing to launch enzyme-catalyzed SAMe API and formulation production, with trial runs scheduled for July. The company has made significant R&D strides, securing patents and offering end-to-end services across the drug development chain.

Park officials note that 75 percent of the first phase's construction has been completed. Once operational, it is expected to generate over 2.5 billion yuan in annual sales and employ more than 600 people. With strategic incentives, targeted investment, and improved infrastructure, Guiyang is positioning itself as a competitive hub for high-end chemical pharma development in West China.